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Abstract 34 
The immune composition of the tumour microenvironment has been shown to regulate processes 35 
including angiogenesis, metastasis and the response to drugs or immunotherapy. To facilitate the 36 
characterisation of the immune component of tumours from transcriptomics data, a number of 37 
immune cell transcriptome signatures have been reported, i.e. lists of marker genes that together 38 
are indicative of the presence a given immune cell population. The majority of these gene signatures 39 
have been defined through analysis of isolated blood cells. However, blood cells have been shown 40 
not to reflect the differentiation or activation state of similar cells within tissues, including tumours, 41 
and consequently perform poorly on tissue data. To address this issue, we generated a set of 42 
immune gene signatures derived directly from tissue transcriptomics data using a network-based 43 
deconvolution approach. We define markers for seven immune cell types, collectively named ImSig, 44 
and demonstrate how they can be used for the quantitative estimation of the immune content of 45 
tumour and non-tumour tissue samples. The utility of ImSig is demonstrated through the 46 
stratification of melanoma patients into immuno-subgroups of prognostic significance and the 47 
identification of immune cells from single-cell RNA-Seq data of derived from tumours. ImSig is 48 
available as an R package (‘imsig’). 49 
 50 
Introduction 51 
Modulating the activity of the immune component of the tumour microenvironment holds great 52 
potential in the treatment of cancer. Checkpoint inhibitors are perhaps the most exciting advance in 53 
cancer therapy in the past decade, with anti-PD1 and CTLA4 antibodies, in particular, demonstrating 54 
remarkable therapeutic results in some patients (1). However, multiple factors within the tumour 55 
microenvironment are recognised to influence the response to immunotherapy, in particular, the 56 
immune infiltrate prior to treatment (2). Immunohistochemistry and flow cytometry have 57 
conventionally been used to study the immune status of tumours, but are limited by the fact that 58 
histological analyses are limited to small areas of tissue and a small numbers of markers, and flow 59 
cytometry requires tissue disaggregation, which may not always be practical. To overcome these 60 
limitations, computational methods have been developed to estimate the immune content of blood 61 
and tissue samples from transcriptomic data (3). Two main approaches are currently used to infer 62 
the relative proportion of cell types from transcriptomic data. A first type of approach fits reference 63 
gene expression profiles from sorted cells to the data in question (4-7) and a second approach, 64 
employs cell-type specific genes to indicate the presence of certain cell populations (8-11). Both 65 
approaches rely on sets of gene markers (gene signatures), however in the first case these genes are 66 
not necessarily cell type-specific in their expression and use supervised learning algorithms to 67 
leverage the additional power needed to distinguish between cell types. 68 
A number of computational frameworks, leveraging these approaches have been described to 69 
estimate the contribution of different immune cell types to the tissue transcriptome (5,10-14). 70 
Across these studies, the range of immune cell types that each method report to detect varies 71 
considerably. For instance, collectively the published studies report gene signatures for 22 T cell 72 
subtypes. Among the signatures that define marker genes, numerous markers are used 73 
interchangeably to define different subtypes and many are expressed by non-immune cell types. 74 
Another, shortfall of these signatures is that they are all derived from cultured or blood-derived 75 
cells. The expression profiles of the same immune cell from blood (PBMC’s) and tissues are 76 
significantly different (15) which compromises the predictive value of signatures (16). 77 
Genes that contribute to a common biological process or define a given cell type are frequently co-78 
regulated, i.e. coexpressed giving rise to expression modules (17,18). We have previously validated 79 
gene correlation network (GCN) analysis of large gene expression datasets from human (including 80 
cancer), mouse, pig and sheep, as a means to define such expression modules (19-21). Here we have 81 
analysed a broad range of human tissue transcriptomic data to identify a set of robustly co-82 
expressed marker genes representing seven immune cell types and three cellular pathway processes 83 
present in many tissue data. We have named this set of signatures, ImSig. We demonstrate the 84 
advantages of ImSig over other reported signatures derived from the comparison of isolated blood 85 
cells and its utility in characterising the immune microenvironment of tumours. 86 
Methods 87 
Derivation of ImSig  88 
Eight publically available expression datasets derived from human tissue were sourced from the 89 
Gene Expression Omnibus (GEO) database (22) (GSE11318, GSE50614, GSE75214, GSE38832, 90 
GSE23705, GSE24383, GSE58812, GSE65904), based on the criteria that the unprocessed data files 91 
were available, they included a variety of normal and diseased samples, represented a variety of 92 
array platforms and contained >20 samples (median size 114 samples). The datasets was chosen 93 
such as to include the diverse variety of immune cell types and differentiation states. Raw Affymetrix 94 
data was processed using oligo package (23) and Illumina data was processed using lumi package 95 
(24) in R. The signal intensities were normalised using the robust multi-array average (RMA) and 96 
genes with multiple probes were summarised into one by choosing the probe with maximum 97 
intensity across samples.  98 
The resultant expression matrix was loaded into the network analysis tool Graphia Professional 99 
(Kajeka Ltd., Edinburgh, UK), previously known as BioLayout Express3D (25,26). Within the tool, a 100 
correlation network was generated (an r value was chosen so as to include approximately 10,000 101 
genes in the analysis) for each dataset and clustered using the Markov Clustering (MCL) algorithm 102 
(27). Clusters were manually annotated based on domain knowledge and with the help of Gene 103 
Ontology (GO) and Reactome pathway enrichment analyses (28,29). The gene modules representing 104 
immune cell types and biological processes were identified for each of the eight datasets. The genes 105 
within the modules were consolidated into a list of genes for seven immune cell types and three 106 
biological processes. In order to identify the core set of genes that represents each cell type or 107 
processes, these genes were further refined/filtered using eight independent validation datasets 108 
(GSE9891, GSE14580, GSE38832, GSE14951, GSE15773, GSE7305, GSE22619, GSE52171) by the 109 
following procedure: Robust cell type/pathway signatures were identified by excluding genes that 110 
were poorly co-expressed using an unbiased approach. Each dataset was loaded into Graphia (r 111 
values were selected so as to include approximately 10,000 genes in the analysis) and clustered 112 
using the MCL algorithm. To model the contribution of noise by random genes within signatures, 0 113 
to 100% of genes within every MCL cluster were replaced with random genes (using the R function 114 
‘sample’) in a stepwise manner, in 2% increments. For each of these replacements, the resultant 115 
median correlation of every cluster was noted. The combined data points were fitted to a sigmoidal 116 
curve using the nonlinear least squares method. Based on this model, we estimated the number of 117 
genes that might contribute to noise within the signatures, and should be filtered out. To facilitate 118 
such inverse estimation, the ‘investr’ package in R was used. For example, based on the median 119 
correlation of signature genes, if the model suggested 30% of genes represented noise, then 30% of 120 
genes exhibiting the poorest median correlation were discarded. This process was repeated for each 121 
signature across the eight validation datasets and the set of genes that survived the filtration 122 
process were defined as ImSig. In essence, the approach sought to identify the most robustly 123 
correlated genes across datasets to arrive at the final list of genes for the individual ImSig signatures. 124 
TopGo was used to identify the five most enriched GO Biological Process (GO_BP) terms associated 125 
with each gene set (28) and p-values were generated using the Fisher-exact test. 126 
Comparison of ImSig with other published signatures 127 
Seven published immune signatures were sourced from the literature (5,8,10-14). To visualise the 128 
concordance between the immune genes defined by the different studies, a chord diagram was built 129 
using circlize package (30) in R. Only genes reported as markers of immune cells were used – ImSig 130 
includes pathway signatures, other studies included signatures for other cells, e.g. fibroblast, 131 
endothelial cells etc. Due to the sheer variety of T cell subtype signatures, these were further 132 
explored to identify gene usage between them. Genes that were present in two or more studies and 133 
ascribed to a T cell or one of its subtypes were identified. Using these genes, a graph was 134 
constructed using Cytoscape (31) and visualised with a circular layout. The size of nodes 135 
representing individual signatures was adjusted according to the number of connections each 136 
signature had with others.  A Jaccard similarity index was also calculated between all signatures. For 137 
the Newman et.al signature genes that were not common between cell types were only considered. 138 
For visualisation of the results, genes pertaining to cell subsets (Treg, Th1) were all pooled to 139 
represent the parent population (T cells) and the Jaccard similarity index was re-calculated. 140 
Comparative analysis of gene signatures in the context of a tissue dataset 141 
Seven immune signatures were sourced from the literature (5,8,10-14). The LM22 signature (5) did 142 
not provide an absolute signature, i.e. same genes may represent multiple cell types and so only a 143 
subset of genes that were unique to cell types was used for this analysis. The median correlation of 144 
the signature genes was calculated within the context of a dataset (GSE20436) generated from 145 
swabs taken from the eyes of children with symptoms of trachoma or controls (32). The dataset 146 
contains transcriptomics data generated from samples taken from three patient subgroups; 20 147 
controls with normal conjunctivas; 20 individuals with clinical signs of trachoma but that tested 148 
negative for the bacteria C. trachomatis (possibly who were in the resolution stage); and 20 149 
individuals with symptoms and active infections. This dataset was chosen due to the well 150 
documented immune infiltration associated with this disease and the presence of all immune 151 
populations defined by ImSig. To be able to directly compare with ImSig, genes pertaining to cell 152 
subsets were all pooled to represent the parent population. In addition, analysis of the median 153 
correlation of non-pooled signatures, i.e. marker sets representing sub-populations of cells, were 154 
also analysed in the context of these data. 155 
To validate ImSig in tumours, transcriptomic data from single-cell suspensions from lymph nodes of 156 
four metastatic melanoma patients were analysed (GSE93722) for which cell type proportions (CD4 T 157 
cells, CD8 T cells, B cells, NK cells) measured with flow cytometry was available. In order to perform a 158 
direct comparison proportions of CD4 and CD8 T cells were summed to estimate total T cell content. 159 
The average expression of ImSig genes were calculated to determine the relative abundance of 160 
immune cells in each patient. The predicted and observed abundance were then scaled between 0 161 
and 1 to be comparable. This analysis also served to validate the applicability of ImSig to RNA-Seq 162 
data. To assess the ability of ImSig to define known clinical differences between patient subgroups 163 
and to illustrate the explorative power of a network-based analysis, we used the trachoma dataset 164 
described above. In order to estimate the relative abundance of immune cells across patient groups, 165 
the average expression of the ImSig signature genes was computed. A two-tailed, unequal variance 166 
t-test was conducted between groups to obtain P-values. To explore the wider context of the 167 
immune environment and extrapolate immune subsets, a GCN (r >0.7) was visualised in Graphia. By 168 
visual inspection of the network graph, immunologically relevant genes (subtype/differentiation-169 
specific) were identified in the vicinity of the ImSig modules and their average expression profile 170 
across patient groups plotted. 171 
Pan-cancer analysis of tumour data (TCGA) 172 
Pre-normalised (level 3 data) transcriptomic data from 12 cancers were downloaded from the TCGA 173 
database. For each cancer type, the patients were ordered based on the average expression of the 174 
individual ImSig signatures and split into two groups based on the median expression value of the 175 
signature genes. In cases such as Brain Lower Grade Glioma (LGG), Kidney Renal Clear Cell Carcinoma 176 
(KIRC) and Uterine Corpus Endometrial Carcinoma (UCEC), B cell signature genes were not co-177 
expressed indicating the likely absence or low abundance of these cells and so were not included in 178 
the survival analysis. A univariate Cox-proportional hazard ratio analysis was performed for the rest 179 
using the survcomp package in R (33). P-values are based on the log-rank test. 180 
Molecular subtyping (patient stratification) of melanoma 181 
RNA-Seq data for the SKCM (human skin cutaneous melanoma) was downloaded from the TCGA 182 
data portal. Using the expression data of ImSig genes, a sample-to-sample correlation plot (r > 0.85) 183 
was generated. MCL clustering (inflation value: 1.7) of the sample-sample correlation plot, grouped 184 
the patients into 5 clusters. These groupings were mapped as a class-set onto the complete GCN to 185 
study the expression patterns of immune cells between groups. A univariate Cox-proportional 186 
analysis was also performed using the survcomp package (33) in R between the groups in various 187 
combinations. The P-value was calculated using the log-rank test.  188 
An independent melanoma dataset- GSE65904 (51) was used for validation. The dataset was 189 
produced on the Illumina HumanHT-12 V4.0 microarrays and composed of samples from 214 190 
melanoma patients. Samples that did not contain necessary information such as disease-specific 191 
survival, gender and sample type were removed. After processing and normalisation using the lumi 192 
package (24) in R, samples that were not present in the network graph (r ≥ 0.8) were also removed 193 
and the remaining samples (210) were processed as described above for the TCGA dataset. 194 
Processing and analysis of single-cell RNA-Seq data 195 
Single-cell transcriptomics data (log2 [(TPM/10)+1]) for melanoma (34) and head and neck cancer 196 
(HNSCC) (35) were downloaded from The Broad Institute single-cell portal 197 
(https://portals.broadinstitute.org/single_cell). As computation of the relative abundance of cell 198 
types is based on the average expression of ImSig genes, missing values in single-cell data can affect 199 
the results. Therefore, to compensate for dropouts, a diffusion-based imputation method was used 200 
to impute missing values (36).  201 
To validate the cell type specificity of ImSig, the average expression of B, T, NK cell and macrophage 202 
signature genes were calculated from the melanoma cell data dataset and compared to the average 203 
expression of the other immune-related ImSig genes. To evaluate the concordance between 204 
estimated abundance and measured number of cells, the average expression of signature genes for 205 
10 patients were computed (estimated abundance). Correlation between estimated abundance and 206 
measured number of cells was calculated and P-values were attained by building a linear regression 207 
model. To visually illustrate the concordance of relative proportions, both the estimated abundance 208 
and measured number of cells were scaled using the formula [x-min(x)/max(x)-min(x), where x is the 209 
cell abundance value] and plotted as a stacked bar plot scaled to 100%.  210 
In order to predict immune cell types in the HNSCC dataset using the SVM-based algorithm 211 
Cibersort, a reference matrix (ImSig as features) was first generated using the melanoma single-cell 212 
data as per the requirements. The algorithm was run with the generated reference matrix and 213 
HNSCC single-cell data, uploaded on to the Cibersort web portal (https://cibersort.stanford.edu). 214 
The output contained a score of B cell, T cell and macrophage for each sample and an associated P-215 
value. P-values of <0.05 and a score of >0.75 (upper quartile) were set as defining correct 216 
predictions, e.g. a T cell score of >0.75 in a T cell with a P-value of <0.05 was judged as a correct 217 
prediction. 218 
R implementation of ImSig 219 
We implemented ImSig as an R package called “imsig”. Users should call the “imsig” function, which 220 
takes a normalized gene expression matrix (HUGO symbols in rows and samples in columns) as its 221 
first argument and a correlation threshold (r) as its second argument. Users can also generate 222 
network graph of ImSig genes and perform survival analysis using the package. A short tutorial is 223 
available at https://github.com/ajitjohnson/imsig. 224 
This package is available at CRAN (https://cran.r-project.org/web/packages/imsig/). 225 
 226 
Results 227 
Derivation of ImSig 228 
Using a network-based approach, a set of co-expressed gene modules associated with human tissue 229 
immune cell populations and frequently observed biological processes were identified from eight 230 
independent tissue transcriptomics datasets. An illustrative example of a gene correlation network 231 
(GCN) is shown in Fig. 1A. These initial gene signatures were further refined and validated by testing 232 
for co-expression of the genes associated with each signature across an additional eight 233 
independent datasets (Fig. 1B). The result was 569 marker genes representative of seven immune 234 
populations (B cells (37 genes), plasma cells (14), monocytes (37), macrophages (78), neutrophils 235 
(47), NK cells (20), T cells (85)) and three biological processes (Interferon response (66), translation 236 
(86), proliferation (99)), named collectively ImSig (Table 1,2 & Supplementary Table S1). The data-237 
driven definition of each immune signature is internally-validated by the association of many well-238 
known markers with the specific signatures, e.g. CD3D and CD3E (T cells), CD19, CD22 and CD79 (B 239 
cells), CD14 (monocytes), CD68 and CD163 (macrophages), KIR family (NK cells) and immunoglobulin 240 
family members (plasma cells). Furthermore, GO enrichment analysis of the gene signatures and 241 
extensive reference to the literature, supported the association of the majority of markers identified 242 
with the relevant cell types and processes. The top 5 enrichment terms for all signatures are listed in 243 
Supplementary Table S2 and the top term is given in Fig. 1C. In contrast to a number of the 244 
published immune gene signatures, we did not define signatures for immune cell sub-types, such as 245 
sub-populations of T cells or activation states of macrophages. Across the diversity of tissue 246 
datasets, we found no support for distinct modules of co-expressed markers describing T cell or 247 
macrophage subpopulations. This is consistent with previous analyses of isolated human 248 
macrophages responding to different stimuli, which did not support the existence of distinct 249 
activation states of macrophages but rather a continuum of difference states depending on the 250 
stimulus (37). Where present, ‘activation-specific’ transcripts such as receptors, cytokines or 251 
transcription factors, tend to form part of the overall cell expression module. By inference, if a 252 
particular gene is strongly co-expressed with a particular cell type-specific signature in the context of 253 
a particular dataset, one can conclude that either it is likely expressed by those cells or at least a sub-254 
population of them. 255 
Comparison between ImSig and published immune signatures 256 
The gene content of seven published immune signatures, all derived from the comparison of isolated 257 
blood cells (5,8,10-14), were compiled and compared, excluding signatures for non-immune cell 258 
types, e.g. endothelial cells, fibroblast etc. When ImSig was added to the list it contained 3,658 259 
genes (Supplementary Table S3). To compare these the gene signatures a Jaccard similarity index 260 
was calculated (Supplementary Table S4) and highlights the poor concordance between signatures 261 
(Supplementary Table S4 and Supplementary Fig. S1). The highest observed similarity was between 262 
ImSig’s and Becht et al.’s B cell signature, Jaccard score = 0.26, which in itself is a not a high Jaccard 263 
score. Fig. 2A illustrates the lack of consensus between published signatures and ImSig, and 264 
highlights the fact that 76.3% of genes are only associated with a single study. Of these 2,794 genes, 265 
only a small proportion described unique populations, e.g. erythroblast (297 genes) and 266 
megakaryocyte (259) described by Watkins et al. The poor conservation of immune marker genes 267 
across studies is likely due to a number of technical and statistical artefacts. For example, 268 
proliferation-related genes were identified as part of the signature for activated CD4 (12) and T cells 269 
(10). The mitotic index of resting versus activated T cells may be a true difference between them, 270 
but cell cycle genes are expressed by all proliferating cells (38) and are therefore poor markers of cell 271 
type. Notably, of all signatures proposed, ImSig contains the fewest unique genes (only 60 ImSig 272 
genes have not been previously been included in other signatures), suggesting a high degree of 273 
consensus with other studies overall, but not particularly with any previous signature alone. 274 
It is also interesting to note the association of certain genes with different cell types in different 275 
studies. Of the 729 genes proposed to represent distinct T cell states, none were common to all 276 
seven studies and only 98 were listed by two or more studies. As Fig. 2B illustrates the assignment of 277 
markers to cell types across studies is highly complicated. For example, LRRN3, was used to define 278 
resting cytotoxic T cells by Abbas et al. and as a Th1 marker by Bindea et al. CTLA4 is annotated as 279 
either a marker of Tregs, Th1 and CD4 T cells and by Angelova et al., Bindea et al., and Watkins et al., 280 
respectively. CTLA4 can also be expressed on CD8+ T cells (39). There are many such examples of 281 
discordance between marker gene/cell type assignations. The ImSig T cell signature, which was 282 
designed to be subtype agnostic, exhibited the greatest overlap between all T cell signatures 283 
(displayed by the relative node size in Fig. 2B) and includes genes defined as subtype-specific by 284 
other studies but for which we found no support as a separate co-expression module. To compare 285 
the co-expression of the ImSig signatures to previous signatures, the median correlation of each set 286 
of signature genes were calculated within the context of a dataset derived trachoma patients. This 287 
was selected as one of the few examples we could find of a dataset derived from a tissue, where all 288 
immune cell types defined by ImSig are present, these being recruited in response to a bacterial 289 
infection. For comparison with previous signatures, those modules representing sub-populations, 290 
e.g. T cell subsets were collated into one, e.g. T cells. Their median correlation in the context of the 291 
trachoma dataset is shown in Fig. 2C. A non-collated version of the results is provided in 292 
Supplementary Table S5. Regardless of whether they were aggregated by broad cell type, or 293 
considered separately; none of the blood-derived modules were strongly co-expressed across the 294 
set of trachoma patient samples. In contrast, all of the ImSig signatures displayed a high median 295 
correlation (co-expression) value. Of the other signatures examined, Becht et al. (8) performed next 296 
best. The bacterial infection that gives rise to the pathology of trachoma leads a significant increase 297 
in the recruitment of immune cells to the site of infection (32). In order to evaluate the ability of 298 
ImSig to estimate the relative abundance of immune cells, the average expression of each gene 299 
signature was used as a proxy for immune cell number in the trachoma dataset. As seen in Fig. 2D, a 300 
significant increase in all immune populations is associated with patient groups relative to controls, 301 
particularly in those patients with an active infection. 302 
Finally, to validate the applicability of ImSig on RNA-Seq data and in the context of tumour biology, 303 
we computed the relative abundance of immune cells in four metastatic melanoma patients for 304 
which single-cell suspensions were collected from lymph nodes. A fraction of the cell suspension was 305 
used to measure cell type proportions by flow cytometry and the other fraction was used for bulk 306 
RNA sequencing. We observed a good agreement (r = 0.91, RMSE = 0.1 and P value = 2.74E-05) 307 
between predictions of relative cell number made using ImSig and experimentally determined cell 308 
numbers (see also Supplementary Fig. S2). This indicates that the relative cell numbers were 309 
accurately predicted for all cell types, as confirmed by the low root-mean-square error (RMSE). 310 
Deconvolution of tissue data 311 
In the context of GCN analyses, the ImSig signatures can be used to identify other context-specific 312 
genes expressed by immune populations. For example, the T cell and macrophage signatures were 313 
correlated with each other, consistent with an immune-mediated inflammatory process, and many 314 
immune-related genes were co-expressed with ImSig genes in the context of the trachoma data (Fig. 315 
3A). The expression profile of genes such as IFNG, LAG3, CD44, FOX03, FOXP3, CD80, IL20, STAT4, 316 
IL17A etc. was correlated with T cell signature genes, indicating that the T cell population included 317 
Th17, Treg and Th1 subtypes (Fig. 3B). Similarly, genes associated with the macrophage signature 318 
contained many classical M1 markers. Network analysis also supports the wider appreciation of the 319 
transcriptional signatures of other cell types present in clinical samples, i.e. when examining the 320 
dataset as a whole, many other GCN clusters can be assigned to other cell populations or processes.  321 
Satisfied with the performance of ImSig in the context of tissue transcriptomics data in general, we 322 
set out to explore its utility in the analysis of transcriptomics data derived from cancer. 323 
Analysis of immune infiltrates in cancer 324 
Our previous analysis of the cancer transcriptome showed that expression signatures of immune 325 
cells can be extracted from large cancer datasets, however, this analysis was not correlated with 326 
outcomes (20). To test the use of ImSig in the study of the tumour microenvironment, the twelve 327 
largest TCGA cancer datasets were examined and hazard ratios were computed between high and 328 
low immune cell infiltrate groups (Fig. 4A). Whilst the survival analysis was not adjusted for 329 
potentially confounding variables (such as tumour stage, grade, age or treatment), the findings were 330 
largely consistent with the literature. In melanoma (SKCM), we reaffirmed the known association 331 
between tumour infiltrating lymphocytes (TIL) and a good prognosis (40,41). Breast cancer (BRCA) is 332 
not as immunogenic as melanoma, but several studies have associated TIL’s with a good prognosis as 333 
observed here (42). A negative association between TIL’s and prognosis was evident in low-grade 334 
glioma (LGG) (43,44) and lung squamous cell carcinoma (LUSC) (45,46) in accordance with the 335 
previous literature. A novel finding was of the potential prognostic value of the interferon response 336 
in low-grade glioma. Another surprising observation was that a high rate of proliferation is 337 
associated with a good prognosis in LUSC and colorectal cancers (COAD). This observation has been 338 
reported previously in colorectal cancer (47), but not in LUSC. Analysis of individual proliferation-339 
related genes in LUSC also supported this observation (log2HR: G2E3- 0.66; MND1- 0.56; CHEK2- 340 
0.53; RFC4- 0.51; CEP192- 0.48; CDKN3- 0.47; CENPA- 0.47; CCND2- 0.47; CDC7- 0.46: p < 0.05). One 341 
possible explanation for this counter-intuitive observation is that the mitotic signal in these tissues 342 
originates from proliferating immune cells, not from cancer itself (48,49).  343 
Extending the analysis above, a molecular subgrouping of melanoma based on ImSig was performed 344 
i.e. only the signature genes were used in the grouping of patient samples. Unsupervised clustering 345 
based on the immune profile revealed five groups of patient samples (Fig. 4B). Clinical features such 346 
as the tissue of origin and tumour type (metastatic or primary) did not affect the subtyping. Nearly 347 
half the patients were in cluster-1, characterised by a low level of immune infiltrate (Fig. 4C). Hazard 348 
ratio (HR) analysis between these low immune (cluster-1) and high immune infiltrate (clusters-2 and 349 
-3) tumours revealed a significant difference in survival (HR: 0.38, p = 3E-9). The median survival of 350 
patients in the high immune group was 10 years greater than that of patients in the low immune 351 
subgroup (Fig. 4D). Within the high immune subgroup, cluster-2 appeared to have a higher level of B 352 
cells and plasma cells in contrast to cluster-3 (Fig. 4C) but overall survival (HR) was not significantly 353 
different between the two groups (Fig. 4D). Cluster-4 samples displayed higher levels of the 354 
interferon response genes and also showed improved survival compared to the low immune group 355 
(Fig. 4D). Finally, patients in cluster-5 had a low immune infiltrate but were enriched for keratin 356 
related genes and presented the worst survival rates (median survival = 2.34 yr). Whilst patients in 357 
clusters-2 and cluster-4 did not show a significant difference in hazard ratio compared to those in 358 
cluster-3, they could potentially show other features, such as differing responses to treatment. 359 
Following an analogous analysis, we were able to reproduce the five patient groupings on an 360 
independent validation dataset (GSE65904) which showed a similar infiltration pattern 361 
(Supplementary Fig. S3A) and survival analysis on the same exhibited similar prognostic pattern 362 
(Supplementary Fig. S3B). High immune and keratin subgroups have been identified and described 363 
previously in melanoma (50,51) but these studies did not describe the type and variation in the 364 
immune infiltrate in melanomas. Our analysis provides a greater degree of granularity as to the 365 
exact nature of the immune landscape of these tumours and consequently improved the prognostic 366 
power. 367 
Use of ImSig in identifying immune cells in single-cell data 368 
To extend these analyses and further validate the ImSig signatures in the context of single-cell data, 369 
we examined single-cell data derived from melanomas (34). The immune component of the 370 
melanoma single-cell analysis included 515 B cells, 126 macrophages, 52 NK cells and 2,069 T cells. 371 
Cell-type specific expression of ImSig markers was observed (P < 7E-15) as illustrated in Fig. 5A. For 372 
each patient, the estimated proportion of immune cells was compared to the true proportion. The 373 
estimated proportion displayed a high degree of concordance with the measured number of cells (p 374 
< 0.05), with the poorest observed correlation being r = 0.97. Randomised permutation analysis with 375 
the same sized gene sets produced no significant correlation (Fig. 5B). Fig. 5C illustrates the 376 
concordance between the measured and estimated number of cells.  377 
The single-cell community depends on gene markers/signatures and clustering algorithms, to define 378 
cell types. Here we have attempted to show the utility of ImSig when used in association of 379 
classification algorithms, such as support vector machine (SVM), to predict cell types from single-cell 380 
RNA-Seq data. To demonstrate such potential for automation, we used the SVM-based 381 
deconvolution tool Cibersort (5) with a reference profile generated with ImSig to predict immune 382 
cells within a single-cell dataset from head and neck tumours (HNSCC) (35). The immune component 383 
of the HNSCC dataset contained 1,473 cells. Prediction using ImSig yielded a high degree of accuracy 384 
for B cells (88.4%), macrophages (98.8%) and T cells (99.8%) (Table 3). 63 immune cells failed to be 385 
categorised into one of the cell types described above (p-value > 0.05). With respect to the other 386 
4,087 cells, i.e. myocytes, mast cells, malignant cells, fibroblast, dendritic cells and endothelial cells, 387 
only 2.2% of cells were misclassified as macrophages, B or T cells. In contrast, Cibersort’s default 388 
blood-derived signature (LM22) showed limited ability to identify immune cell types in these data, 389 
with an accuracy rate for B cells of 15.2%, macrophages, 0% and T cells, 75.3%. However, LM22 390 
signature was not designed to deconvolute single-cell data and its poor performance is likely a 391 




Cellular heterogeneity is a hallmark of cancer, both in terms of the tumours themselves and the 396 
normal cells that both support and control their growth. There is now a wealth of transcriptomics 397 
data generated from cancer samples and there have been a number of previous studies that report 398 
approaches to deconvolute these data in an attempt to define the set of cell types present therein. 399 
However, we and others (16) found that immune signatures derived by comparing the expression 400 
profile of immune cells isolated from blood, do not perform optimally when applied to tissue data.  401 
The current work is based on the observation that genes associated with a specific cell population or 402 
biological process form highly connected cliques of nodes (Fig. 1A) when large collections of 403 
transcriptomics data are subjected to network-based correlation analysis (18,52). Whilst the main 404 
goal of this study was to define immune gene signatures for the deconvolution of cancer data, we 405 
have derived ImSig from a range of tissue pathologies and platforms to ensure its applicability across 406 
different data types and sources. Our aim in defining ImSig was to choose the most robustly co-407 
expressed genes for each cell immune cell type directly from the analysis of tissue data, thereby 408 
defining a ‘core’ or invariant cell type-specific signature.  409 
In any given tissue, a gene may be expressed by multiple cell types present therein or a cell type may 410 
not be present, hence the need to explore a wide variety of tissue data. We also chose to include 411 
signatures for interferon signalling, proliferation (mitosis) and translation, as these are commonly 412 
observed co-expression modules in tissue and act as additional controls. Validatory analysis of the 413 
resultant ImSig signatures showed the gene signatures to be highly enriched with appropriate GO 414 
terms (Fig. 1C) and manual inspection of the lists with reference to the literature, also supported the 415 
validity of the selected genes. This was further confirmed by the observed co-expression of the ImSig 416 
signatures across a wide range of datasets not used for their derivation and their average expression 417 
following changes in immune cell numbers, where known, e.g. in trachoma.  418 
As the current study is by no means the first to attempt to define sets of signatures for immune cells, 419 
we sought to compare ImSig with other published signatures, both in terms of gene content and 420 
performance. Definition of cell signatures is not trivial, nor is simple to compare signatures across 421 
studies. In the first instance, the published gene signatures all vary in terms of the number of genes 422 
they include and the cell populations and sub-populations they seek to define. Secondly, there is no 423 
benchmark dataset where the number and nature of immune cells are known in the context of a 424 
tissue environment. Comparison of the signatures showed many to include gene markers only 425 
defined by that study, and where common to more than one study, there was a highly complex 426 
relationship between the assignation of genes to cells across studies; in other words, there is little 427 
consensus across published immune marker lists (Figs. 2A&B). What was apparent is that of all the 428 
signatures, ImSig contained the fewest unique genes (65), suggesting that rather than the gene 429 
content of ImSig being particularly novel, it represents more of a consensus view of other studies, 430 
despite being derived independently from them. The comparison of the performance of signatures 431 
again represented a challenge. Where multiple subtypes of cells were defined, the genes associated 432 
with subtypes were either analysed separately or collapsed into a single signature. We chose to 433 
compare the performance of these summarised signatures in the context of the trachoma dataset, 434 
where we knew all immune cell types to be present and that their relative level increases during 435 
active infection (32). In this context, the degree of co-expression between genes associated with 436 
individual ImSig signatures was in many cases dramatically better than others (Fig. 2C). Furthermore, 437 
the average expression of ImSig signatures mirrored the known increase in immune cell infiltrate 438 
during across patient groups (32) (Fig. 2D). 439 
Ever since the first description of major types of immune cells, researchers have sought to define 440 
sub-types, i.e. sub-populations and activation states associated with different tissues, developmental 441 
stages and pathologies. Whilst heterogeneity amongst immune cell populations undoubtedly exists, 442 
the number of markers that definitively identify them outside of the context of flow cytometry and 443 
immunohistochemical experiments or comparison of isolated populations, is limited. For instance, 444 
tissue macrophages are named differently depending on their tissue of origin (microglia, Kupffer 445 
cells etc.) or activation state (M1, M2 etc.) and in other cases are referred to as dendritic cells 446 
(53,54). Across the previous studies referred to here, signatures for 22 T cell subsets are reported 447 
and this does not include all T cell subsets that are defined in the literature (55). In addition, in a 448 
given pathological state multiple cellular subtypes or populations whose biology is adapted to 449 
different niches are likely to be present. We would argue that it is unrealistic to expect to be able to 450 
categorically identify their individual signatures from bulk tissue data, especially when the 451 
differences between them are more likely to be a spectrum than a series of absolute states (37). 452 
Even amongst different myeloid populations, i.e. monocytes, macrophages and neutrophils, we have 453 
found very few markers that are entirely specific to one population or another, and the markers 454 
selected to define the presence of these populations, do so more by their co-expression than 455 
absolute expression in the context of tissue. 456 
Whilst we suggest that many immune subtype markers are too poorly defined to reliably distinguish 457 
immune cell subsets in the context of transcriptomics data derived from tissue, network analysis can 458 
provide a comprehensive picture of the immune microenvironment. By examination of the genes 459 
that closely correlate with the core signature genes (Fig. 3B), even if one cannot with any degree of 460 
certainty assign their expression to one cell type or another, it is possible to capture the overall 461 
profile the immune microenvironment of a tissue in health or disease. It may after all be the sum of 462 
the individual parts that matter. How one translates these finding into immune subset identification 463 
we leave to the individual analyst, with the cellular subtypes they recognise and the marker genes 464 
that define them. 465 
After satisfying ourselves of the validity of ImSig and its superiority over other signatures in defining 466 
immune populations in tissue data, we used it to analyse a broad spectrum of large transcriptomics 467 
datasets derived from 12 cancer types. In each case, the majority of signature genes were tightly co-468 
expressed, apart from instances where we believe the target cell was not present or there in low 469 
abundance. When the samples for each tumour type were ranked according to their immune cell 470 
content (as defined by the average expression of the signature genes), we were able to demonstrate 471 
a clear variation in the immune microenvironment between tumours and the association of specific 472 
immune cell populations with a good or poor prognoses (Fig. 4A). Despite an established association 473 
between the immune system and survival in melanoma (56), there has been little effort to subgroup 474 
patients based upon specific immune cell types present, previous studies merely defining tumours as 475 
having a high or low immune content (51,57). We, therefore, explored the use of ImSig in the 476 
molecular subtyping melanoma patients. The analysis demonstrated a greater heterogeneity in the 477 
immune infiltrate of melanoma than previously reported (50,51) with tumours that have: high levels 478 
of T cells, macrophages (cluster 3); a high interferon enrichment (cluster 4); and tumours with high B 479 
cell infiltration (cluster 2). This analysis highlights the fact that by treating the immune infiltrate of 480 
tumours as an overall signature, loses the potential to identify prognostically significant subgroups. 481 
In other cases merging the immune infiltrate into one immuno-subgroup might result in opposing 482 
survival differences cancelling each other out, e.g. if T cells were associated with a good prognosis 483 
and macrophages a bad prognosis. Understanding the immune heterogeneity tumours may also be 484 
key in predicting their response to immunotherapy (58,59). 485 
The advent of single-cell transcriptomics and its application to understanding the microenvironment 486 
of cancer promises to facilitate the profiling of all the cells of a tumour as never before possible (60) 487 
and may eventually circumvent the need to deconvolute tissue data, as described here. The 488 
technology to perform these analyses is improving rapidly and may in the future answer many of the 489 
questions about immune cell heterogeneity. However, at the present time, the data available is 490 
limited and the droplet-based RNA sequencing methods being widely used may not provide a 491 
sufficient depth of sequencing to go beyond the identification of cell type. Here we demonstrate 492 
how ImSig was able to define the type and relative abundance of immune cells in single-cell data 493 
derived from melanoma, and head and neck cancer with a high degree of accuracy. This both further 494 
validates the signatures and demonstrates how they may be used in this context. As the quantity 495 
and quality of single-cell cancer datasets improve and we understand the expression profile of these 496 
cells in many contexts is better appreciated, perhaps then reliable markers may be defined that are 497 
able to differentiate between immune subtypes or activation states, specifically in the context of the 498 
tumour microenvironment. 499 
ImSig is the first immune signature to be directly derived from tissue data. Although its gene content 500 
is not necessarily novel in the context of those reported previously, we believe it to be superior to 501 
published immune signatures in terms of being a robust, subtype agnostic means to estimate the 502 
relative abundance of these cells across tissue samples. We also demonstrate the ability of ImSig to 503 
be a powerful companion for the identification of novel biomarkers when applied in the context of 504 
network co-expression analyses. We anticipate that ImSig will prove to be a valuable resource for 505 
studying immune cell variation in tumour samples and how they respond to therapy, aiding in the 506 
discovery of novel predictive biomarkers. 507 
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AFF3, BANK1, BLK, BTLA, CCR6, CD180, CD19, CD22, CD37, CD72, CD79A, CD79B, 
CR2, EBF1, FAM129C, FCRL1, FCRL2, FCRL3, FCRL5, FCRLA, HLA-DOB, IGHV5-78, 
KIAA0125, LINC00926, LOC100507616, LY9, MS4A1, P2RX5, PAX5, PNOC, POU2F2, 
S1PR4, SNX22, STAP1, TCL1A, TLR10, VPREB3 
T cells 
 
AMICA1, APBB1IP, ARHGAP15, ARHGAP25, ARHGAP9, BIN2, BTK, C1orf162, CCL19, 
CCR7, CD2, CD27, CD28, CD3D, CD3E, CD3G, CD48, CD52, CD6, CD8A, CD96, 
CORO1A, CRTAM, CXCL9, CXCR6, CYTIP, DOCK10, DOCK2, DOCK8, DPEP2, EVI2A, 
EVI2B, FAM26F, FLI1, FYB, FYN, GAB3, GIMAP2, GIMAP4, GIMAP5, GIMAP6, 
GIMAP7, GMFG, GPR171, GPR18, GZMK, HCST, HMHA1, HVCN1, ICOS, IL10RA, IL16, 
IL23A, IL7R, ITGAL, ITK, KLHL6, KLRB1, LCP1, LY86, NCF1B, NLRC3, PARVG, PRKCH, 
PSTPIP1, PTPRCAP, PVRIG, RASSF5, RCSD1, RGS18, RHOH, SASH3, SH2D1A, SIRPG, 




ADAMDEC1, ADORA3, AOAH, ARRB2, ATP8B4, BCL2A1, C1orf54, C1QA, C1QB, C2, 
C3AR1, C5AR1, CCR1, CCRL2, CD163, CD300A, CD4, CD68, CD74, CD86, CECR1, 
CLEC7A, CMKLR1, CSF1R, CTSB, CTSS, CYBB, CYTH4, DPYD, EMR2, FCER1G, FCGR1A, 
FCGR1B, FCGR2A, FCGR3B, FPR3, GPNMB, HK3, HLA-DRB6, IFI30, IGSF6, ITGAM, 
ITGAX, ITGB2, LAIR1, LAPTM5, LILRB4, LIPA, LY96, MAN2B1, MFSD1, MNDA, 
MS4A4A, MS4A7, MSR1, MYO1F, NCKAP1L, NPL, NR1H3, PLA2G7, PLEKHO2, 
SCPEP1, SLAMF8, SLC15A3, SLC31A2, SLCO2B1, SNX10, SPI1, TBXAS1, TLR8, 
TMEM140, TNFAIP2, TNFRSF1B, TNFSF13B, TRPV2, TYMP, TYROBP, VSIG4 
Monocytes 
 
AGTRAP, AIF1, C10orf54, CD14, CD300LF, CD33, CD93, CTSD, EMILIN2, FCN1, FES, 
FGR, GNS, GRN, HCK, HMOX1, KIAA0930, LILRA6, LILRB2, LILRB3, LRRC25, LST1, 
NFAM1, NOTCH2, PILRA, PLXDC2, PRAM1, PSAP, PYCARD, RHOG, SERPINA1, SLC7A7, 
TGFBI, THEMIS2, TIMP2, TPP1, VCAN 
Neutrophils 
 
ACSL1, ALPK1, AQP9, BASP1, BCL6, CD97, CEP19, CFLAR, CSF3R, CXCR2, DENND5A, 
DYSF, FAM65B, FCGR2C, FPR1, GLT1D1, GPR97, IFITM2, IL17RA, KCNJ2, KIAA0247, 
LILRA2, LIMK2, LINC01002, MGAM, MOB3A, NAMPT, NCF4, PADI2, PHC2, PHF21A, 
PLXNC1, PREX1, RALB, RNF149, S100A8, S100A9, SLC25A37, SNORD89, SSH2, STAT3, 
STAT5B, THBD, TLR2, TLR4, TMEM154, TNFRSF1A 
NK cells 
 
KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DS1, KIR2DS2, KIR2DS3, 




GUSBP11, IGH, IGHG3, IGJ, IGKC, IGKV1D-13, IGLC1, IGLJ3, IGLL3P, IGLV@, IGLV1-44, 








Table-2: Table of ImSig genes (Pathways Signatures) 690 
Interferon 
 
APOL1, APOL6, BATF2, BST2, C19orf66, C5orf56, CMPK2, DDX58, DDX60, DHX58, 
DTX3L, EPSTI1, FBXO6, GBP1, GBP4, HELZ2, HERC5, HERC6, HSH2D, IFI16, IFI35, 
IFI44, IFI44L, IFI6, IFIH1, IFIT1, IFIT2, IFIT3, IFIT5, IFITM1, IRF7, IRF9, ISG15, LAMP3, 
LAP3, MX1, MX2, OAS2, OAS3, OASL, PARP10, PARP12, PARP14, PARP9, PHF11, 
PML, PSMB9, RNF213, RSAD2, RTP4, SAMD9, SAMD9L, SHISA5, SIGLEC1, SP110, 




ANLN, ASPM, AURKA, AURKB, BIRC5, BUB1, BUB1B, CASC5, CCNA2, CCNB1, CCNB2, 
CCNE2, CDC20, CDC6, CDCA2, CDCA3, CDCA5, CDCA7, CDCA8, CDK1, CDKN3, CDT1, 
CENPA, CENPE, CENPF, CENPL, CEP55, CKS1B, DEPDC1, DEPDC1B, DLGAP5, 
DONSON, DTL, E2F8, ECT2, EZH2, FAM72C, FANCI, FBXO5, FOXM1, GINS1, GINS2, 
GMNN, HJURP, HMGB3, HMMR, KIAA0101, KIF11, KIF14, KIF15, KIF18B, KIF20A, 
KIF2C, KIF4A, MAD2L1, MCM10, MCM2, MCM4, MCM6, MELK, MKI67, MND1, 
MTFR2, NCAPG, NCAPG2, NDC80, NEK2, NUF2, NUSAP1, OIP5, PARPBP, PBK, PCNA, 
PLK4, POLE2, POLQ, PTTG1, RACGAP1, RAD51, RAD51AP1, RRM1, RRM2, SHCBP1, 
SKA1, SMC2, SPC25, STIL, STMN1, TCF19, TK1, TOP2A, TPX2, TRIP13, TTK, TYMS, 
UBE2C, UHRF1, ZWILCH, ZWINT 
Translation 
EEF1A1, EEF1B2, EEF1D, EEF1G, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3K, FAU, 
GNB2L1, NACA, PFDN5, RPL10, RPL10L, RPL11, RPL12, RPL13, RPL13A, RPL14, 
RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL27, 
RPL27A, RPL28, RPL29, RPL3, RPL30, RPL31, RPL32, RPL34, RPL35, RPL35A, RPL36A, 
RPL37, RPL37A, RPL38, RPL39, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPLP0, 
RPLP2, RPS10, RPS11, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS18, RPS19, 
RPS2, RPS20, RPS21, RPS23, RPS25, RPS27A, RPS28, RPS29, RPS3, RPS3A, RPS5, 
RPS6, RPS7, RPS8, RPS9, RPSA, SNHG6, SNHG8, SNRPD2, UXT 
 691 
Table-3: Identification of immune cells within single-cell data. ImSig was used in conjunction with 692 
the SVM based classifier Cibersort, to identify immune cells within the head and neck tumour 693 
(HNSCC) single-cell data. The table shows the accuracy of identification. 63 immune cells were 694 
unassigned as its p-value was greater than 0.05. 695 








B cells 122 16 88.4 11.6 
Macrophages 84 1 98.8 1.2 
T cells 1185 2 99.8 0.2 
Other cells (4087 
cells) 
  93   2.3 
 696 
Figure Legends 697 
Figure 1: Derivation of ImSig. (A) An illustrative example of a correlation network generated from a 698 
tissue dataset where nodes represent unique genes and edges represent correlations between them 699 
above a defined threshold. Groups of nodes sharing the same colour represent gene modules 700 
(obtained by MCL clustering), those highlighted being associated with a given immune cell type or 701 
biological process. (B) Example plots from the approach used to refine the gene signatures. Blue 702 
points represent genes that were kept, i.e. they were highly correlated with other genes in the 703 
preliminary signature and red represents genes that were discarded. This approach was applied to 704 
eight tissue datasets (only 2 shown here), the most robustly coexpressed genes across the datasets 705 
being used to define ImSig. (C) Bar plot depicting the number of genes within each marker gene 706 
signature comprising ImSig and the top GO enrichment term for each signature. 707 
Figure 2: Comparison of ImSig with other published signatures. (A) Chord diagram showing the 708 
overlap between marker genes across studies. In most studies, a significant proportion of genes 709 
were unique to the signatures defined by them, while ImSig showed the best overlap (81%) with 710 
other studies. (B) Network diagram showing the relationship between T cell subtype-specific genes 711 
among six studies and ImSig. Only genes that were present in two or more studies are represented 712 
(98 genes i.e. 13.4%) for this plot. Nodes are sized relative to the number of shared genes between 713 
one signature and others. ImSig was found to be inclusive of genes describing various subtypes and 714 
was the most conserved set among all studies compared. (C) Heatmap of the median correlation 715 
between genes from published signatures as assessed in the context of the trachoma dataset 716 
(GSE20436). Where a cell type signature was split into subsets, subset signatures were combined to 717 
represent the parent population. The median correlation values of signatures without combining 718 
them into parent population is also available (Supplementary Table S4). (D) Bar plots of the average 719 
expression of signature genes (estimated relative abundance) across the dataset, each bar 720 
representing the average expression of signature genes in an individual patient sample. Samples are 721 
ordered according to T cell content, low-high, (left-right) and this order is maintained for other plots. 722 
Figure 3: Coexpression of other immune genes with ImSig core signatures. (A) Correlation network 723 
of genes associated with the immune clusters during trachomatis infection. ImSig genes are coloured 724 
according to the different immune cell types they represent, while the genes co-clustering with the 725 
ImSig immune genes are shown as nodes without colour and reduced in size. Highlighted with a 726 
greater node size and label are a few well known immune modulatory genes present in the 727 
immediate vicinity of the signature genes. (B) Bar plots of the average expression intensity of a few 728 
well known immune modulatory genes across the three patient groups.  729 
Figure 4: Application of ImSig to tumour data. (A) Prognostic map of 12 cancer types based on 730 
immune cell content. The average expression of each ImSig signature was calculated for each 731 
sample/tumour type. Samples were then ordered according to each signature (low-high, black plot 732 
in each square) and the hazard ratio calculated between the lowest and highest expressing samples. 733 
Blue represents a good prognosis with increased expression of the signature genes and red a poor 734 
prognosis. * = a HR P-value < 0.05. BCLA-Bladder Urothelial Carcinoma, BRCA-Breast invasive 735 
carcinoma, COAD-Colon adenocarcinoma, HNSC-Head and Neck squamous cell carcinoma, KIRC-736 
Kidney renal clear cell carcinoma, LGG-Brain Lower Grade Glioma, LUAD-Lung adenocarcinoma, 737 
LUSC-Lung squamous cell carcinoma, PRAD-Prostate adenocarcinoma, SKCM-Skin Cutaneous 738 
Melanoma, THCA-Thyroid carcinoma, UCEC-Uterine Corpus Endometrial Carcinoma. (B) Sample-739 
sample correlation plot based on expression of ImSig genes in melanoma patients and clustered 740 
using MCL algorithm. Here every node is a patient and the edges correspond to the correlation 741 
between them. (C) Expression profile of ImSig related genes within the various clusters/grouping as 742 
defined in B. Here the y-axis is the average expression of the signature genes and x-axis are the 743 
patient groupings as shown in B. (D) Univariate Cox proportional analysis between the patient 744 
groups as defined in B. 745 
Figure 5: Validation of ImSig using single-cell RNA-seq data from melanoma samples. (A) The 746 
immune component of the melanoma single-cell data displayed as a correlation network, each node 747 
representing a cell from melanoma. Box plots display the average expression of cell type-specific 748 
ImSig genes in their respective cell types compared to the average expression of other ImSig genes. 749 
Process-specific ImSig signature genes (proliferation, interferon and translation) were omitted in this 750 
analysis. (B) Linear regression plots showing the concordance between the estimated and measured 751 
abundance of immune cells in ten patients. For five patients (P1, P3, P5, P7, P9), the regression line 752 
was also calculated using a random set of genes to highlight the specificity of ImSig genes. (C) 753 
Stacked bar plots showing the concordance between measured and estimated proportions of 754 
immune cells. 755 





